Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Current Deferred Revenue (2024 - 2025)

Prime Medicine (PRME) has disclosed Current Deferred Revenue for 2 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue rose 10.32% year-over-year to $7.8 million, compared with a TTM value of $7.8 million through Dec 2025, up 10.32%, and an annual FY2025 reading of $7.8 million, up 10.32% over the prior year.
  • Current Deferred Revenue was $7.8 million for Q4 2025 at Prime Medicine, up from $7.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $9.3 million in Q3 2024 and bottomed at $7.0 million in Q3 2025.